Trial
NCT02658396
GO-203-2C + Bortezomib For Relapsed Or Refractory MM
Phase IWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Dana-Farber Cancer Institute
Collaborators
Genus Oncology, LLC; National Institutes of Health (NIH)
Condition
Multiple Myeloma
Intervention
GO-203-2C
Why stopped
Study was never open due to lack of funding
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-07-05